AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims

1-51. (Cancelled)

52. (Currently Amended) A pharmaceutical composition comprising particles comprising a polymeric material, a biologically active agent capable of generating a protective immune response in an animal or a human, a cationic pluronic and an immunostimulant amount of N-carboxymethyl chitosan or a salt thereof, wherein the biologically active agent and the immunostimulant amount of N-carboxymethyl chitosan or the salt thereof are encapsulated in microspheres or microparticles comprising a polymeric material of a molecular weight 94 kDa or more.

53-55. (Cancelled)

- 56. (Previously Presented) The composition of claim 52, wherein the polymeric material has a molecular weight of 100kDa or more.
 - 57. (Cancelled)
- 58. (Previously Presented) The composition of claim 52, wherein the polymeric material is poly-(L-lactide).
- 59. (Previously Presented) The composition of claim 52, wherein the biologically active agent is capable of generating the protective immune response against tetanus, anthrax, diphtheria or *Yersinia pestis*.
- 60. (Previously Presented) The composition of claim 52, wherein the biologically active agent comprises a combination of the V antigen of Y. pestis or an immunologically active fragment thereof, and the F1 antigen of Y. pestis or an immunologically active fragment thereof.

Amendment and Response to Final Office Action and RCE U.S. Application Serial No. 09/937,066
Page 3 of 13

61. (Previously Presented) The composition of claim 52, further comprising one or more chemical compounds selected from the group consisting of a polyamino acid, a vitamin, a vitamin derivative a clathrate, a complexing agent, a cetrimide, an S-layer protein, a methyl-glucamine, a cationic polypeptide, a cationic polyamino acid, and a quaternary ammonium compound.

62. (Cancelled)

63. (Currently Amended) A pharmaceutical composition comprising <u>a polymeric</u> <u>microparticle surface modified or coated with N-carboxymethyl chitosan or a salt thereof particle comprising a polymeric material, a cationic pluronic and [[a]] <u>an adsorbed onto the microparticle</u> biologically active agent capable of generating a protective immune response in an animal or a human, wherein the particles are coated with the N-carboxymethyl chitosan or a salt thereof, and the biologically active agent is adsorbed onto the coated particles.</u>

64-65. (Cancelled)

- 66. (Currently Amended) The composition of claim 62, wherein the <u>polymeric</u> microparticle comprises a polymeric material has a molecular weight of 100kDa or more.
 - 67. (Cancelled).
- 68. (Currently Amended) The composition of claim [[62]] <u>66</u>, wherein the polymeric material is poly-(L-lactide).
- 69. (Currently Amended) The composition of claim [[62]] <u>63</u>, wherein the biologically active agent is capable of generating the protective immune response against tetanus, anthrax, diphtheria or *Yersinia pestis*.
- 70. (Currently Amended) The composition of claim [[62]] <u>63</u>, wherein the biologically active agent comprises a combination of the V antigen of Y. pestis or an immunologically active fragment thereof, and the F1 antigen of Y. pestis or an immunologically active fragment thereof.

Amendment and Response to Final Office Action and RCE U.S. Application Serial No. 09/937,066 Page 4 of 13

- 71. (Currently Amended) The composition of claim [[62]] 63, further comprising one or more chemical compounds selected from the group consisting of a polyamino acid, a vitamin, a vitamin derivative, a clathrate, a complexing agent, a cetrimide, an S-layer protein, a methylglucamine, a cationic polypeptide, a cationic polyamino acid, and a quaternary ammonium compound.
- 72. (New) A pharmaceutical composition comprising a biologically active agent capable of generating a protective immune response in an animal or a human and an immunostimulant amount of N-carboxymethyl chitosan or a salt thereof, wherein the biologically active agent and the immunostimulant amount of N-carboxymethyl chitosan or the salt thereof are encapsulated in microspheres or microparticles comprising a polymeric material of a molecular weight 94 kDa or more, and wherein the N-carboxymethyl chitosan or the salt thereof is present in the pharmaceutical composition in an amount of from 0.15 to 10% w/w.
- 73. (New) The composition of claim 52, wherein the microspheres or the microparticles are on average from $0.1 \, \mu m$ to $10 \, \mu m$ in diameter.